DE60042903D1 - Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen - Google Patents

Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen

Info

Publication number
DE60042903D1
DE60042903D1 DE60042903T DE60042903T DE60042903D1 DE 60042903 D1 DE60042903 D1 DE 60042903D1 DE 60042903 T DE60042903 T DE 60042903T DE 60042903 T DE60042903 T DE 60042903T DE 60042903 D1 DE60042903 D1 DE 60042903D1
Authority
DE
Germany
Prior art keywords
retroviral
response
vector
preparation
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042903T
Other languages
English (en)
Inventor
Pierre Charneau
Hueseyin Firat
Veronique Zennou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60042903D1 publication Critical patent/DE60042903D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60042903T 1999-10-11 2000-10-10 Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen Expired - Lifetime DE60042903D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99402492A EP1092779B1 (de) 1999-10-11 1999-10-11 Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen

Publications (1)

Publication Number Publication Date
DE60042903D1 true DE60042903D1 (de) 2009-10-15

Family

ID=8242139

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69941703T Expired - Lifetime DE69941703D1 (de) 1999-10-11 1999-10-11 Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
DE60028066T Expired - Lifetime DE60028066T2 (de) 1999-10-11 2000-10-10 Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
DE60042903T Expired - Lifetime DE60042903D1 (de) 1999-10-11 2000-10-10 Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69941703T Expired - Lifetime DE69941703D1 (de) 1999-10-11 1999-10-11 Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
DE60028066T Expired - Lifetime DE60028066T2 (de) 1999-10-11 2000-10-10 Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen

Country Status (15)

Country Link
US (3) US7968332B2 (de)
EP (4) EP2169073B1 (de)
JP (2) JP4663943B2 (de)
CN (2) CN1379820B (de)
AT (3) ATE449858T1 (de)
AU (3) AU785060B2 (de)
CA (1) CA2387182C (de)
CY (4) CY1105149T1 (de)
DE (3) DE69941703D1 (de)
DK (4) DK1092779T3 (de)
ES (4) ES2447115T3 (de)
HK (2) HK1093523A1 (de)
IL (2) IL148901A0 (de)
PT (4) PT2169073E (de)
WO (1) WO2001027300A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
ES2447115T3 (es) 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DK1224314T3 (da) 1999-10-12 2007-05-21 Inst Nat Sante Rech Med Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1412493B1 (de) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor-produktionssystemen
EP1438075A4 (de) 2001-10-02 2006-04-19 Inst Clayton De La Rech Verfahren und zusammensetzungen in verbindung mit lentiviralen vektoren mit begrenzter expression und ihre anwendungen
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EP1712241A1 (de) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Intratumoral applizierbare Zusammensetzung zur Krebsbehandlung
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
EP1739092A1 (de) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidische Antagonisten von Klasse III Semaphorin/Neuropilin Komplexen
EP1748067A1 (de) 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
WO2007054814A1 (en) 2005-11-14 2007-05-18 Centre National De La Recherche Scientifique - Cnrs Inhibitors of parp activity and uses thereof
EP3293266A1 (de) 2007-05-04 2018-03-14 University Health Network Il-12-immuntherapie gegen krebs
CN102083462B (zh) * 2007-08-03 2015-02-18 巴斯德研究院 慢病毒基因转移载体及其医学应用
EP2385107B1 (de) 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
EP2666477A1 (de) 2012-05-23 2013-11-27 Theravectys Lentivirale Vektoren mit einem MHC-Klasse-I-Promotor
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
NO2788478T3 (de) 2011-12-09 2018-01-20
US20150182617A1 (en) 2012-07-25 2015-07-02 Theravectys Glycoproteins for pseudotyping lentivectors
WO2015063707A1 (en) 2013-10-31 2015-05-07 Theravectys LENTIVIRAL VECTORS FOR INDUCING CD4+ and CD8+ IMMUNE RESPONSES IN VACCINATION OF HUMANS
EP3009144A1 (de) 2014-10-15 2016-04-20 Theravectys Lentivirale Vektoren zur Induzierung von CD4+- und+CD8+-Immunreaktionen bei der Impfung von Menschen
EP3087188A1 (de) 2013-12-23 2016-11-02 Theravectys Lyophilisierte lentiviren-vektor-partikel, zusammensetzungen daraus und verfahren
CN106163552A (zh) 2014-01-27 2016-11-23 赛拉福柯蒂斯公司 用于产生针对人嗜t‑淋巴病毒1型的免疫应答的慢病毒载体
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
EP3511413B1 (de) 2014-07-25 2022-09-07 Theravectys Lentivirale vektoren zur regulierten expression eines chimären antigenrezeptormoleküls
EP3031923A1 (de) 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
EP3410849B1 (de) 2016-02-05 2023-07-05 Institut Pasteur Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
EP3211003A1 (de) 2016-02-24 2017-08-30 Institut Pasteur T-zell-rezeptoren aus dem hiv-spezifischen repertoire, mittel zu deren herstellung und therapeutische verwendung davon
EP3276006A1 (de) 2016-07-27 2018-01-31 Theravectys Lentivirale vektoren zur expression von hepatitis-b-virus (hbv)-antigenen
EP3357506A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Mehrere malaria-prä-erythrozyten-antigene und deren verwendung bei der auslösung einer schützenden immunantwort in einem wirt
EP3357504A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Funktionelles screening von antigenen polypeptiden verwendung zur identifizierung von antigenen zur anregung einer schützenden immunantwort und zur auswahl von antigenen mit optimaler schutzwirkung
EP3648776A4 (de) 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. Neue in-vitro- und in-vivo-anreichungsstrategie gegen lymphozyten aus vektortransduzierten hsc zur behandlung von erkrankungen
EP3697809A1 (de) 2017-10-20 2020-08-26 Institut Curie Für rush angepasste dap10/12-basierte cars
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
CN108118070A (zh) * 2018-01-15 2018-06-05 南京驯鹿医疗技术有限公司 一种慢病毒制备方法
CN108588028B (zh) * 2018-04-26 2021-11-09 中国人民解放军军事科学院军事医学研究院 一种靶向cdkn2a的cic细胞模型及其制备方法
WO2020229893A1 (en) 2019-05-10 2020-11-19 Institut Pasteur Live imaging system to visualize the retro-transcribed viral dna genome
CA3182333A1 (en) 2020-05-20 2021-11-25 Institut Curie Single domain antibodies and their use in cancer therapies
WO2022013405A1 (en) 2020-07-15 2022-01-20 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
WO2022167831A1 (en) 2021-02-02 2022-08-11 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20240053339A1 (en) 2020-09-21 2024-02-15 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
EP4225382A2 (de) 2020-10-07 2023-08-16 Asklepios Biopharmaceutical, Inc. Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
EP3984548A1 (de) 2020-10-16 2022-04-20 Institut Pasteur Generation von lentiviralen vektoren, die es ermöglichen, antigene zum mhc-ii-weg zu leiten und cd4+- und cd8+-t-zellantworten als immunantwort in einem wirt zu induzieren
EP4229090A1 (de) 2020-10-16 2023-08-23 Université d'Aix-Marseille Anti-gpc4-einzeldomänenantikörper
IL304031A (en) 2021-01-14 2023-08-01 Inst Curie Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
CN116981777A (zh) 2021-03-12 2023-10-31 巴斯德研究所 靶向mhc-ii途径抗原并在宿主中诱导保护性cd8+和cd4+t细胞免疫的慢病毒载体
AU2022386715A1 (en) 2021-11-15 2024-05-16 Institut Pasteur Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
WO2024023135A1 (en) 2022-07-27 2024-02-01 Theravectys Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
WO2024084041A2 (en) 2022-10-21 2024-04-25 Institut Pasteur Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684094A5 (de) * 1988-03-21 1994-07-15 Viagene Inc Rekombinante Retroviren.
GB9213559D0 (en) * 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
JPH06261764A (ja) 1993-02-17 1994-09-20 Wisconsin Alumni Res Found 混合型ｌｔｒ含有超複合型レトロウイルス及びその使用方法
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000506727A (ja) * 1996-03-05 2000-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
AU7158398A (en) 1997-04-17 1998-11-11 Regents Of The University Of California, The Use of lentiviral vectors for antigen presentation in dendritic cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
JP4291508B2 (ja) * 1997-10-10 2009-07-08 アメリカ合衆国 癌胎児性抗原（ｃｅａ）のアゴニストおよびアンタゴニストペプチド
EP1030684A4 (de) * 1997-11-14 2004-09-15 Euro Celtique Sa Modifizierte antikörper mit verstärkter fähigkeit eine anti-idiotypische antwort auszulösen
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6555342B1 (en) * 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en) 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
ES2447115T3 (es) 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DK1224314T3 (da) 1999-10-12 2007-05-21 Inst Nat Sante Rech Med Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
DE60028066D1 (de) 2006-06-22
HK1049861A1 (en) 2003-05-30
IL148901A0 (en) 2002-09-12
ATE326541T1 (de) 2006-06-15
AU2010203111B2 (en) 2012-01-19
AU1143501A (en) 2001-04-23
EP1650309B1 (de) 2009-09-02
CY1110551T1 (el) 2015-04-29
DE60028066T2 (de) 2007-01-18
CY1105149T1 (el) 2010-03-03
JP5265643B2 (ja) 2013-08-14
EP1092779A1 (de) 2001-04-18
CN1379820B (zh) 2011-04-13
EP1092779B1 (de) 2009-11-25
CA2387182A1 (en) 2001-04-19
JP2003511080A (ja) 2003-03-25
PT1650309E (pt) 2009-11-18
EP1650309A1 (de) 2006-04-26
US20130157357A1 (en) 2013-06-20
DE69941703D1 (de) 2010-01-07
EP1222300B1 (de) 2006-05-17
JP2011078420A (ja) 2011-04-21
DK1222300T3 (da) 2006-09-18
CA2387182C (en) 2010-12-21
PT2169073E (pt) 2014-02-20
ATE449858T1 (de) 2009-12-15
HK1093523A1 (en) 2007-03-02
ATE441721T1 (de) 2009-09-15
DK2169073T3 (da) 2014-02-10
CN1840204A (zh) 2006-10-04
ES2337429T3 (es) 2010-04-23
WO2001027300A1 (en) 2001-04-19
EP1222300A1 (de) 2002-07-17
CY1114819T1 (el) 2016-12-14
AU785060B2 (en) 2006-09-14
AU2006252062B2 (en) 2010-04-22
CN1840204B (zh) 2011-09-07
ES2332930T3 (es) 2010-02-15
US7968332B2 (en) 2011-06-28
US20040081636A1 (en) 2004-04-29
ES2447115T3 (es) 2014-03-11
CY1110611T1 (el) 2015-04-29
ES2262545T3 (es) 2006-12-01
AU2006252062A1 (en) 2007-01-18
EP2169073B1 (de) 2013-11-13
PT1222300E (pt) 2006-09-29
CN1379820A (zh) 2002-11-13
PT1092779E (pt) 2010-01-19
DK1092779T3 (da) 2010-02-15
HK1049861B (zh) 2006-12-22
JP4663943B2 (ja) 2011-04-06
EP2169073A1 (de) 2010-03-31
US20110250650A1 (en) 2011-10-13
AU2010203111A1 (en) 2010-08-12
DK1650309T3 (da) 2009-11-30
IL204703A0 (en) 2010-11-30
US8652807B2 (en) 2014-02-18
US8349606B2 (en) 2013-01-08

Similar Documents

Publication Publication Date Title
DE60042903D1 (de) Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
AU7994887A (en) Hair products containing dimethyl diallyl ammonium chloride/acrylic acid-type polymer
UA19765A (uk) Фрагмеhт hуклеїhової кислоти, що кодує людський проаполіпопротеїн а-1
GR3025721T3 (en) Ampholyte terpolymers providing superior conditioning properties in shampoos and other hair care products
EP0278940A3 (de) Hepatitis-B-Virus-Oberflächenantigene und sie enthaltende hybride Antigene
ATE179323T1 (de) Haarpflege- und fixierungsmittel
EP1652857A3 (de) Fusionsprotein des regulatorische/akzessorische HIV Proteine
EP1409694A4 (de) Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
DK0630409T3 (da) Defekt-pakkende ikke-onkovirus-vektorer baseret på MPMV
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
EP0832266A4 (de) Orale verabreichung von vektoren, die vom adenoassoziierten virus abgeleitet sind
EP1840209A3 (de) Adeno-assoziierten Virusvektoren und deren Verwendung.
ATE296314T1 (de) Peptide des env-gens vom katze immunschwäche- virus und deren verwendung
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2005027844A3 (en) Dna vaccine compositions and methods of use
WO1999003981A8 (en) Nucleic acid expression constructs incorporating a heterologous intron whose natural position is within the 5'untranslated region of its gene
SE9503379D0 (sv) A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
WO2023172963A3 (en) Recombinant aav vectors and uses thereof
EP1568775A4 (de) Krebs-assoziiertes gen
WO1999014333A3 (en) Improved method of production of pneumococcal surface proteins
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen
WO2004003010A3 (en) Nuclear hormone receptor ligano-binding domain containing protein
BR9908649A (pt) Composição de vacina
TH12620EX (th) สารผสมสเปรย์ฉีดผมซึ่งมีสารลดแรงตึงผิวฟลูออโร

Legal Events

Date Code Title Description
8364 No opposition during term of opposition